Jeffrey M Holzbeierlein, MD

Dr. Jeffrey Holzbeierlein is physician in chief at The University of Kansas Cancer Center and the William L. Valk Endowed Professor at the University of Kansas Medical Center. He specializes in the treatment of genitourinary malignancies including bladder, kidney, testicular and penile cancers. His research interests include the Hsp90 inhibitors in bladder cancer and clinically decreasing the morbidity associated with cystectomy.

Dr. Holzbeierlein was raised in Edmond, Oklahoma, and received his undergraduate degree from Vanderbilt University. He earned his medical degree at the University of Oklahoma and completed his internship and residency at Vanderbilt University. He joined the faculty at the medical center after he completed his fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center, New York.

Dr. Holzbeierlein is on the executive board of directors and is a past president of the south-central section of the American Urological Association. He is president for the Society of Urologic Oncology and is past chair of the fellowship committee and serves on the executive board of the SUO. For this work, he received the SUO Distinguished Service Award in 2013.

Dr. Holzbeierlein has served on the American Board of Urology Oncology knowledge assessment examination committee and is a past assistant editor for the Journal of Urology. He currently is a member of the oral boards committee for the American Board of Urology and has served on numerous AUA committees, including the practice guidelines committee and the public media committee, and he has completed the AUA Leadership Program.

He has been on the steering committee for the American Society of Clinical Oncology Genitourinary Cancers and is also the past chair and founding member of the young urologic oncologists section of the Society of Urologic Oncology. He is a reviewer for the Journal of Urology, Cancer and Urologic Oncology. He has also been awarded the Resident Mentoring Award for faculty at The University of Kansas Hospital.

Dr. Holzbeierlein has published numerous peer-reviewed journal articles and has numerous presentation and abstracts in journals and textbooks dealing with urologic oncology. He has been an annual lecturer for an AUA course focusing on the management of high-risk bladder cancer that was selected as one of the “best courses” at the AUA. He has intramural and extramural grant support, including a co-investigator role on an R01, and he is the principal investigator on a SWOG trial.

He lives in Kansas City with his wife, Jill, and their 4 children.

Academic Profile

https://www.kucancercenter.org/find-a-researcher/researcher-finder-results/jeffrey-holzbeierlein-md-facs